Tenoxicam and Phenethyl Isothiocyanate Combination Therapy Mitigates Aβ₁₋₄₂-Induced Alzheimer's Pathology in Rats
Background
Effective disease-modifying therapies for Alzheimer's disease (AD), a progressive neurodegenerative disorder marked by cognitive decline, neuroinflammation, and oxidative stress, remain limited. Current approaches often fall short in addressing the multifaceted pathology. This study targets the critical interplay between neuroinflammation and oxidative stress, key drivers of neuronal damage in AD, by exploring a combinatorial strategy. Specifically, it investigates the synergistic potential of an anti-inflammatory drug and a potent antioxidant to modulate the NF-κB/NLRP3 signaling pathway and restore redox homeostasis.
Study Design
Male Wistar rats were induced with Aβ₁₋₄₂ to model AD and assigned to control, disease, standard, Tenoxicam, Phenethyl Isothiocyanate (PEITC), and combination treatment groups. Cognitive performance was rigorously assessed using the Morris Water Maze, Y-maze, and Novel Object Recognition tests. Neuroinflammatory and oxidative stress markers, including NF-κB, NLRP3, IL-1β, Nrf2, catalase, and malondialdehyde, were quantified. Histopathological examination of hippocampal integrity was performed, complemented by molecular docking studies against COX-2, NF-κB, and NLRP3 targets.
Results
Aβ₁₋₄₂ administration successfully induced significant cognitive impairment, neuroinflammation, oxidative stress, and neuronal damage in the disease model. Both Tenoxicam and PEITC monotherapies demonstrated beneficial effects across multiple parameters. They improved behavioral performance in cognitive tests, reduced inflammatory signaling (e.g., NF-κB, NLRP3, IL-1β), and restored antioxidant defenses by enhancing Nrf2 activity and catalase levels while reducing malondialdehyde. These treatments also preserved hippocampal architecture, indicating neuroprotective effects. Molecular docking confirmed binding affinities to key inflammatory targets. > The combination of Tenoxicam and PEITC consistently showed the most pronounced and synergistic improvements across all assessed cognitive, biochemical, and histological endpoints, significantly surpassing individual monotherapies. This suggests a powerful dual modulation of inflammatory and redox pathways.
Key Findings
- Aβ₁₋₄₂ administration induced significant cognitive impairment, neuroinflammation, and oxidative stress in rats.
- Tenoxicam and PEITC monotherapies improved behavioral performance and reduced inflammatory markers.
- Both compounds restored antioxidant defenses and preserved hippocampal architecture.
- The combination of Tenoxicam and PEITC demonstrated the most pronounced improvements across all endpoints.
- Molecular docking supported the interaction of compounds with
COX-2,NF-κB, andNLRP3.
Why It Matters
This preclinical study highlights a promising multi-target approach for Alzheimer's disease by simultaneously addressing neuroinflammation and oxidative stress, two critical and interconnected pathological hallmarks. For biohackers and clinicians, this suggests that combining agents with complementary mechanisms, such as an NSAID and an Nrf2 activator, could offer superior neuroprotection compared to single-agent therapies. While still in preclinical stages, this combinatorial strategy provides a strong rationale for further investigation into a potentially more effective AD treatment protocol. The practical takeaway is the validation of a synergistic effect when targeting multiple AD pathways, potentially leading to future protocols that integrate anti-inflammatory and antioxidant compounds for enhanced cognitive preservation.
alzheimers-disease
neuroinflammation
oxidative-stress
tenoxicam
phenethyl-isothiocyanate
nf-kb